To include your compound in the COVID-19 Resource Center, submit it here.

Zynerba falls on Phase II cannabidiol miss

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) fell $8.39 (56%) to $6.67 on Monday after reporting that its synthetic cannabidiol (CBD) gel ZYN002 missed the primary endpoint

Read the full 245 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE